Flavin-containing monooxygenase 3 as a potential player in diabetes-associated atherosclerosis
Open accessThe DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Abstract
Despite the well-documented association between insulin resistance and cardiovascular disease, the key targets of insulin relevant to the development of cardiovascular disease are not known. Here, using non-biased profiling methods, we identify the enzyme flavin-containing monooxygenase 3 ( Fmo3 ) to be a target of insulin. FMO3 produces trimethylamine N-oxide (TMAO), which has recently been suggested to promote atherosclerosis in mice and humans. We show that FMO3 is suppressed by insulin in vitro , increased in obese/insulin resistant male mice and increased in obese/insulin-resistant humans. Knockdown of FMO3 in insulin-resistant mice suppresses FoxO1, a central node for metabolic control, and entirely prevents the development of hyperglycaemia, hyperlipidemia and atherosclerosis. Taken together, these data indicate that FMO3 is required for FoxO1 expression and the development of metabolic dysfunction.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Insights into the mechanisms through which the meta-organismal pathway responsible for TMAO production are associated with enhanced CVD risks have thus far focused on the involvement of TMAO and FMO3 in atherosclerotic plaque development, altered sterol and glucose metabolism, and changes in macrophage phenotype (Wang et al., 2011 ; Koeth et al., 2013; Miao et al., 2015 ; Shih et al., 2015; War”
From Gut Microbial Metabolite TMAO Enhances Platelet Hyperreactivity and Thrombosis Risk (2016) · cites this paper as Miao et al., 2015
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Knockdown of FMO3 in LIRKO mice suppressed FoxO1 expression (and improved glucose tolerance) by upregulating sterol regulatory element binding protein 2 (SREBP2) (77).”
From Trimethylamine N -Oxide, the Microbiome, and Heart and Kidney Disease (2017) · cites this paper as [77]
In the citing paper
“suppression of the host enzyme, FMO3, through antisense oligonucleotide-based approach, results in reduction of both circulating TMAO levels and diet-enhanced atherosclerosis in animal models”
From Non-lethal Inhibition of Gut Microbial Trimethylamine Production for the Treatment of Atherosclerosis (2015) · cites this paper as Miao et al., 2015
In the citing paper
“Taken together, these data suggest that FMO3, which is differentially regulated in male and female mice, is necessary but apparently not sufficient for the development of the diabetic phenotype.”
From Implication of Trimethylamine N-Oxide (TMAO) in Disease: Potential Biomarker or New Therapeutic Target (2018) · cites this paper as [76]
In the citing paper
“downregulation or knock-out of FMO3 leads to decreased levels of TMAO and it is athero-protective in these models, whereas increased expression of FMO3 leads to pro-atherogenic lipid profiles (e.g., higher VLDL and LDL) [75,76].”
From Implication of Trimethylamine N-Oxide (TMAO) in Disease: Potential Biomarker or New Therapeutic Target (2018) · cites this paper as [76]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease
Wang, Z., Klipfell, E., Bennett, B. J., Koeth, R., Levison, B. S., DuGar, B., Feldstein, A. E., Britt, E. B., Fu, X., Chung, Y.-M., et al. (2011) · Nature · doi:10.1038/nature09922 · Cited by 5,597
affy—analysis of Affymetrix GeneChip data at the probe level
Gautier, L., Cope, L., Bolstad, B. M., & Irizarry, R. A. (2004) · Bioinformatics · doi:10.1093/bioinformatics/btg405 · Cited by 5,218
SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver
Horton, J. D., Goldstein, J. L., & Brown, M. S. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15593 · Cited by 4,794
Cardiovascular Morbidity and Mortality Associated With the Metabolic Syndrome
Isomaa, B., Almgren, P., Tuomi, T., Forsén, B., Lahti, K., Nissén, M., Taskinen, M.-R., & Groop, L. (2001) · Diabetes Care · doi:10.2337/diacare.24.4.683 · Cited by 4,760
Intestinal microbiota metabolism of l-carnitine, a nutrient in red meat, promotes atherosclerosis
Koeth, R. A., Wang, Z., Levison, B. S., Buffa, J. A., Org, E., Sheehy, B. T., Britt, E. B., Fu, X., Wu, Y., Li, L., et al. (2013) · Nature Medicine · doi:10.1038/nm.3145 · Cited by 4,386
SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver
Horton, J. D., Goldstein, J. L., & Brown, M. S. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215593 · Cited by 4,092
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk
Tang, W. H. W., Wang, Z., Levison, B. S., Koeth, R. A., Britt, E. B., Fu, X., Wu, Y., & Hazen, S. L. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1109400 · Cited by 3,400
Grundy, S. M., Benjamin, I. J., Burke, G. L., Chait, A., Eckel, R. H., Howard, B. V., Mitch, W., Smith, S. C., & Sowers, J. R. (1999) · Circulation · doi:10.1161/01.cir.100.10.1134 · Cited by 2,698
The Metabolic Syndrome: Time for a Critical Appraisal
Kahn, R., Buse, J., Ferrannini, E., & Stern, M. (2005) · Diabetes Care · doi:10.2337/diacare.28.9.2289 · Cited by 2,378
Research works printed but not linked: 2
- Shih, D. M. et al. Flavin containing monooxygenase 3 exerts broad effects on glucose and lipid metabolism and atherosclerosis. J Lipid Res 56, 22–37 (2015) . · DOI · Paper page
- Roberts, L. D., Souza, A. L., Gerszten, R. E. & Clish, C. B. Curr. Protoc. Mol. Biol eds Frederick M. A.et al. Chapter 30, Unit 30 32 31-24 (2012) .
Cited by
Items 301–372 of 372
Hong, S., Lu, J., Li, J., Luo, Y., Liu, D., Jin, Y., Wang, Z., Wang, Y., Zhang, H., Zhang, X., et al. (2024) · Cardiovascular Toxicology · doi:10.1007/s12012-024-09932-8 · Cited by 4
Li, B., Yang, S., Ye, J.-R., Chu, S., Chen, N., & An, Z. (2021) · Neuroscience Letters · doi:10.1016/j.neulet.2021.136222 · Cited by 4
Yang, Z., Stemmer, P. M., & Petriello, M. C. (2022) · Toxics · doi:10.3390/toxics10020060 · Cited by 4
Song, J., Shi, X., Li, X., Liang, Q., Zeng, L., Li, G., Yan, Y., Xu, G., & Zheng, J. (2022) · Frontiers in Veterinary Science · doi:10.3389/fvets.2022.868602 · Cited by 4
“in cholesterol and lipid metabolism, Glu metabolism, diabetesrelated traits, and vascular inflammation (7, 9, 11, 39).”
BackgroundPutro, P. S., Indarto, D., Purwanto, B., Soewondo, W., Kusumaningrum, S., & Nguzum, K. Y. (2023) · Pharmacognosy Journal · doi:10.5530/pj.2022.14.166 · Cited by 4
Do we Have the Gut to Beat Thrombosis?
Tsante, K. A., Petrou, E., Tsalas, S., Tsantes, A. G., Lianou, A., Kartelias, G., Kyriakou, E. S., Kokoris, S. I., Nikolopoulos, G. K., Bonovas, S., et al. (2025) · Seminars in Thrombosis and Hemostasis · doi:10.1055/a-2704-8487 · Cited by 5
Integrating TMAO into the pathogenesis of obesity and type 2 diabetes: a mini review
Stoian, D. L., Pescari, D., Bena, A., Paul, C., & Mihuta, S. (2026) · Frontiers in Clinical Diabetes and Healthcare · doi:10.3389/fcdhc.2026.1765794 · Cited by 3
Gan, Y., Ruan, D., Zeng, Q., Zhu, Y., Hu, Y., Wu, R., Lin, X.-F., Wu, J., Meng, X., Luo, J.-W., et al. (2023) · PubMed Central · Cited by 3
Huang, M., Duan, S., Zhang, Q., Guo, L., Qin, Z., & Yang, J. (2024) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2024.106538 · Cited by 3
The Paradox of Increased Trimethylamine-N-Oxide Levels Following Bariatric Surgery
Devaraj, S., & Jialal, I. (2016) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2016.29005.dev · Cited by 3
“Also alterations in bile acid metabolism and a decrease in hepatic steatosis could be advanced as potential mechanisms, resulting in increase in TMAO levels because of an increase in FMO3 activity.(10) Furthermore, they rule out renal impairment as a cause for the increase in TMAO levels because there was a decrease i…”
BackgroundCholine and phosphatidylcholine
Klatt, K. C. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821848-8.00020-2 · Cited by 3
Sadegh, H. R., & Choi, J. P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26178622 · Cited by 2
Trimethylamine N-oxide participates in human diseases by causing endoplasmic reticulum stress
Kumari, K., Arora, A., Natarajan, N., Ansari, N. A., & Singh, L. R. (2025) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2025.130900 · Cited by 2
The Gut-Brain Axis: A Critical Link between Type 2 Diabetes and Parkinson’s disease
Almohmadi, N. H., Al‐kuraishy, H. M., Hussein, K. S., Turkistani, A., Yousef, F. M., Al-Gareeb, A. I., Abdelaziz, A. M., Elewa, Y. H. A., & Batiha, G. E. (2026) · Probiotics and Antimicrobial Proteins · doi:10.1007/s12602-026-11014-w · Cited by 5
“Notably, some GM species like Lactobacillus plantarum inhibit the expression of hepatic flavin-monooxygenase 3, which is involved in glucose and lipid metabolism as well as the development of IR [26].”
The Microbiome Epoch: Cracking the Cardiovascular-Neurodegenerative Disorder Code
Parolini, C., & Amedei, A. (2026) · Frontiers in Bioscience-Landmark · doi:10.31083/fbl47174 · Cited by 2
Shyshkan-Shyshova, К. О., & Zinych, О. В. (2022) · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · doi:10.22141/2224-0721.18.4.2022.1177 · Cited by 2
“В експериментальному дослідженні виявлено, що зниження вмісту FMO3 у інсулінорезистентних мишей може зменшувати вироблення TMAO і повністю запобігати розвитку гіперглікемії, гіперліпідемії та атеросклерозу у тварин [32].”
Structure–Function Analysis of Liver Flavin Monooxygenase 3 that Drives Trimethylaminuria in Humans
Chhibber‐Goel, J., Singhal, V., Gaur, A., Yogavel, M., & Sharma, A. K. (2017) · Proceedings of the National Academy of Sciences India Section B Biological Sciences · doi:10.1007/s40011-017-0913-5 · Cited by 2
Applications of Metabolic Phenotyping in Pharmaceutical Research and Development
Everett, J. R. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-812293-8.00014-1 · Cited by 3
Role of the Microbiome in Cardiovascular Disease
Chaikijurajai, T., Wilcox, J. D., & Tang, W. H. W. (2021) · Contemporary cardiology · doi:10.1007/978-3-030-78177-4_15 · Cited by 2
SCFAs in T1D: A microbiota-targeted approach for immune tolerance
Mariño, E. (2022) · Current Opinion in Endocrine and Metabolic Research · doi:10.1016/j.coemr.2022.100355 · Cited by 2
Yam, P., VerHague, M., Albright, J., Gertz, E., de Villena, F. P., & Bennett, B. J. (2022) · Genes & Nutrition · doi:10.1186/s12263-022-00714-x · Cited by 2
“Intriguingly, studies in the mouse have suggested additional roles for FMO3 in health and disease, such as modulating cholesterol metabolism [96], glucose, and lipid homeostasis [78], and as a target for downregulation by insulin [58].”
BackgroundMehta, J. K., Banerjee, M., Shah, P. H., Kaur, G., & Buttar, H. S. (2023) · Advances in biochemistry in health and disease · doi:10.1007/978-3-031-14952-8_14 · Cited by 4
Gut Microbiota and Risk for Atherosclerosis: Current Understanding of the Mechanisms
Dutta, B., Biswas, C., Arya, R. K., & Rahaman, S. O. (2020) · Springer eBooks · doi:10.1007/978-3-030-47384-6_8 · Cited by 1
Microbiome-Targeted Therapies: Enhancing Resilience in Metabolic Disorders
Janiad, S., & Rehman, K. (2024) · Springer eBooks · doi:10.1007/978-981-97-3790-1_13 · Cited by 2
Key roles of Drosophila flavin-containing monooxygenases in lipid metabolism and longevity
Wei, Q., Xue, Y., Fan, J., & Su, J. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.146851 · Cited by 1
What Is the Involvement of Gut Microbiome in the Pathophysiology of Diabetes?
Kiełbowski, K., Plewa, P., Zadworny, J., Stodolak, P., Jędrasiak, A., Bakinowska, E., & Pawlik, A. (2025) · Biomolecules · doi:10.3390/biom15101463 · Cited by 1
“Excessive FMO3 activity has been linked to hypergly-caemia and hyperlipidaemia, while its suppression is associated with improved insulin sensitivity in insulin-resistant mice [48,54,55].”
Alvarado, S. J., Enciso, M. F. F., Amedei, A., & Aguirre‐García, M. M. (2026) · World Journal of Cardiology · doi:10.4330/wjc.v18.i3.116780 · Cited by 1
Pathophysiology and pharmacotherapy of cardiovascular complications in metabolic syndrome
Dhalla, N. S., Patel, C. A., Beladiya, J., Mehta, A. A., & Gandhi, T. R. (2026) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2026.04.007 · Cited by 1
Acierno, C., Caturano, A., Barletta, F., Rinaldi, L., Sasso, F. C., Adinolfi, L. E., & Nevola, R. (2026) · Frontiers in Physiology · doi:10.3389/fphys.2026.1881697 · Cited by 2
Douzinas, E. E., & Apeiranthitis, A. (2019) · Springer eBooks · doi:10.1007/978-981-13-8946-7_23 · Cited by 1
Relationship between non-alcoholic fatty liver disease and cardiovascular disease
Chi, Z.-C. (2020) · World Chinese Journal of Digestology · doi:10.11569/wcjd.v28.i9.313 · Cited by 1
Gut microbiota and their effects on atherosclerosis, platelet function, and hypertension
Duttaroy, A. K. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-822405-2.00022-0 · Cited by 1
Gut bacterial metabolite TMA induces hepatic metabolic stress and inflammation via mediation of A20
Kaluzny, S., & Su, Q. (2021) · Proceedings of The Nutrition Society · doi:10.1017/s0029665121002287 · Cited by 1
NMR Metabolomics for Marker Discovery of Metabolic Syndrome
Quesada‐Vázquez, S., Hernández-Baixauli, J., Navarro‐Masip, È., & Escoté, X. (2022) · Biomarkers in disease · doi:10.1007/978-3-031-07389-2_39 · Cited by 1
LEVERAGING SMALL MOLECULES TO MODULATE THE MICROBIOME TO TREAT HUMAN DISEASES
Gulati, A., & Guo, X. (2022) · Medicinal chemistry reviews · doi:10.1021/mc-2022-vol57.ch16 · Cited by 1
Shokati, S., Sargazi, S., Majidpour, M., Mirinejad, S., Ghale-Noie, Z. N., Shahraki, M., Sargazi, S., & Piri, M. (2025) · Indian Journal of Clinical Biochemistry · doi:10.1007/s12291-024-01295-9 · Cited by 1
Effects of Egg Intake on Choline Metabolism and HDL Functionality in a Healthy Population
Lemos, B. S. (2019) · OpenCommons at University of Connecticut (University of Connecticut) · Cited by 1
Wilson, S. M. (2018) · Montana State University ScholarWorks (Montana State University)
Prokopienko, A. J. (2019) · D-Scholarship@Pitt (University of Pittsburgh)
Novel Mediators of Diabetes-Associated Cardiovascular Disease
Gearing, M. E. (2017) · Digital Access to Scholarship at Harvard (DASH) (Harvard University) · Cited by 1
Self-citationMICROBIOTA INTESTINALE E RISCHIO CARDIOVASCOLARE
Sircana, A., Paschetta, E., Cassader, M., Gambino, R., & Musso, G. (2020) · il Diabete · doi:10.30682/ildia1903a
Gut Microbial Dysbiosis and Cardiovascular Diseases
Gasmi, A., Noor, S., Piscopo, S., & Berthouze, S. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-819265-8.00050-4
Snapshots of the past: studies on extant and extinct flavin-containing monooxygenases
Bailleul, G. (2021) · University of Groningen research database (University of Groningen / Centre for Information Technology) · doi:10.33612/diss.180618224
NMR Metabolomics for Marker Discovery of Metabolic Syndrome
Quesada‐Vázquez, S., Hernández-Baixauli, J., Navarro‐Masip, È., & Escoté, X. (2022) · Biomarkers in disease · doi:10.1007/978-3-030-81304-8_39-1
Metabolic Regulation of Longevity by Flavin-containing Monooxygenase 2
Choi, C. (2022) · Deep Blue (University of Michigan) · doi:10.7302/6251
Breisch, J. (2022) · Publication Server of Goethe University Frankfurt am Main (Goethe University Frankfurt) · doi:10.21248/gups.71261
Kardiyovasküler hastalıklarda bağırsak mikrobiyotasının rolü
Kökcü, E., Akil, Ü., & Asil, E. (2022) · Toros University Journal of Food Nutrition and Gastronomy · doi:10.58625/jfng-1934
Exploring the Potential Effect Study of Morinda citrifolia and PCOS Based on Network Pharmacology
许, 宝. (2023) · Advances in Clinical Medicine · doi:10.12677/acm.2023.1361413
Regulation of Trimethylamine N-oxide in Treatment of Cardiometabolic Diseases. Doctoral Thesis
Ozola, M. (2023) · doi:10.25143/prom-rsu_2023-16_dt · Cited by 2
Monoamine Oxidases and Flavin-Containing Monooxygenases
Cashman, J. R. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95488-4.00004-8 · Cited by 1
Huang, Z., Liu, C., Zhao, X., & Guo, Y. H. (2025) · Archives of Physiology and Biochemistry · doi:10.1080/13813455.2025.2489721
“Previous studies have shown that the level of FMO3 is related to the action of insulin and the level of FMO3 in the liver is significantly increased in insulin resistance, diabetic mouse models, and morbid obesity (Miao et al., 2015).”
Gut Microbe-Derived Trimethylamine Shapes Circadian Rhythms Through the Host Receptor TAAR5Preprint
Mahen, K. K., Massey, W. J., Orabi, D., Brown, A. L., Jaramillo, T. C., Burrows, A. C., Horak, A. J., Dutta, S., Mrdjen, M., Mouannes, N., et al. (2025) · eLife · doi:10.7554/elife.107037.1 · Cited by 1
Mao, Y., Gu, N., Ma, X., Wang, Y., Yu, N., Lu, D., Tong, L., Guo, X., Zhang, J., Gao, Y., et al. (2025) · International Journal of Endocrinology · doi:10.1155/ije/1020054
“In insulin-resistant mice, FMO3 knockdown reduces Forkhead box O1, a metabolic regulatory node, ameliorating hyper-glycemia, hyperlipidemia, and atherosclerosis [8].”
Tan, Z., Ding, C., Li, J., Cao, T., Liu, L., Song, Y., Chen, P., Zhang, Y., Li, J., Huo, Y., et al. (2024) · Precision Nutrition · doi:10.1097/pn9.0000000000000075
Li, S.-Y., Chen, S., Lu, X.-T., Fang, A.-P., Chen, Y.-M., Huang, R.-Z., Lin, X.-L., Huang, Z.-H., Ma, J.-F., Huang, B.-X., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20517119
Yam, P., VerHague, M., Albright, J., Gertz, E., de Villena, F. P., & Bennett, B. J. (2022) · Figshare · doi:10.6084/m9.figshare.20461935
Taesuwan, S. (2018) · eCommons (Cornell University) · doi:10.7298/x48050vv
Impact of Gut Microbiota on Platelet Function
Duttaroy, A. K. (2025) · Springer eBooks · doi:10.1007/978-3-031-96352-0_9
Gut Microbe-Derived Trimethylamine Shapes Circadian Rhythms Through the Host Receptor TAAR5Preprint
Mahen, K. K., Massey, W. J., Orabi, D., Brown, A. L., Jaramillo, T. C., Burrows, A. C., Horak, A. J., Dutta, S., Mrdjen, M., Mouannes, N., et al. (2025) · eLife · doi:10.7554/elife.107037.2
Suchecka, N. A., Popławska, P., Obrycka, P., Frątczak, A., Tokarz, E., Soczyńska, J., & Woźniak, S. (2026) · Biomedicines · doi:10.3390/biomedicines14020287
“In humans, however, such a gender distinction is much less evident or even absent [46].”
Vasudevan, D. (2026) · World Journal of Diabetes · doi:10.4239/wjd.v17.i3.113843
The metabolic milieu of tuberculosis-type 2 diabetes mellitus comorbidity using 1H-NMR metabolomicsPreprint
Terblanche, S. E., Mason, S., Kleynhans, L., Ronacher, K., & Loots, D. T. (2026) · Research Square · doi:10.21203/rs.3.rs-9167983/v1
Metabolic and Endocrinological Aspects of Gut Microbiota
Longo, S., Antonetti, L., Casagrande, V., Antonucci, A., Mollace, R., Menghini, R., & Federici, M. (2026) · Endocrinology · doi:10.1007/978-3-030-71067-5_13-1
Tang, J., Zaretsky, J. A., Labajo, J. D., Shaqo, A., Dakroub, H., Shelp, G. V., Poole, E. M., Burns, S. E., & Cho, C. E. (2026) · iScience · doi:10.1016/j.isci.2026.116720
“24 More broadly, the handling of TMA and TMAO is clinically relevant”
Wang, B., Yang, Y., Ho, Y. M., Lin, H., Yuan, J., Long, K., Cheng, K. K. Y., & Li, X. (2026) · Nature Communications · doi:10.1038/s41467-026-76075-5
“FMO3istraditionallyregardedasahepaticenzyme,recentstudies showed that it can also be detected in the aorta, adrenal gland, and thyroid in rodents 8,86 .”
InfluentialHepatic FMO3 Downregulation Contributes to the Metabolic Benefits of Vertical Sleeve Gastrectomy
Yan, H., Cao, C., Tan, X., Huang, X., Liu, Y., Chu, Y., He, M., Yao, Q., Hua, R., & Shao, Y. (2026) · Obesity · doi:10.1002/oby.70281
Feng, X., Yang, Q., Ren, Y., Liu, Y., & Xu, J. (2026) · Scientific Reports · doi:10.1038/s41598-026-69053-w
Metadata
- Authors
- Miao, J., Ling, A. V., Manthena, P. V., Gearing, M. E., Graham, M. J., Crooke, R. M., Croce, K. J., Esquejo, R. M., Clish, C. B., Morbid Obesity Study Group, Torrecilla, E., Vázquez, G. F., Rubio, M. A., Cabrerizo, L., Barabash, A., Pernaute, A. S., Torres, A. J., Vicent, D., & Biddinger, S. B.
- Affiliations
- Boston Children's Hospital (US)
- Ionis Pharmaceuticals (United States) (US)
- Brigham and Women's Hospital (US)
- Sanford Burnham Prebys Medical Discovery Institute (US)
- Broad Institute (US)
- Carlos III Hospital (ES)
- Hospital Clínico San Carlos (ES)
- Universidad Complutense de Madrid (ES)
- Corresponding author
- Biddinger, Sudha B.
- ORCID
- Venue
- Nature Communications
- Published
- 2015-04-07
- Volume
- 6
- Issue
- 1
- Pages
- 6498-6498
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC4391288
- OpenAlex
- W2094278898
- Cited by
- 368
- References
- 58
- Citations by year
- 2026: 16 · 2025: 29 · 2024: 26 · 2023: 35 · 2022: 41 · 2021: 40 · 2020: 44 · 2019: 30 · 2018: 33 · 2017: 29 · 2016: 35 · 2015: 9
- FWCI
- 30.96
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- RePEc: Research Papers in Economics (submittedVersion)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- American Heart Association
- Brigham and Women's Hospital
- Wake Forest University
- Broad Institute
- Institut National de la Santé et de la Recherche Médicale
- Sociedad de Endocrinología, Nutrición y Diabetes de la Comunidad de Madrid
- National Heart, Lung, and Blood Institute (R01HL048044, HL48044, HL109650, R01HL109650)
- National Institute of Diabetes and Digestive and Kidney Diseases (L40 DK065607, K99DK100539, DK-100539, R00DK100539)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
- Keywords
- FMO3, insulin resistance, diabetes-associated atherosclerosis, trimethylamine N-oxide, FOXO1, obesity, hyperglycemia, hyperlipidemia, metabolic dysfunction, insulin signaling
- MeSH terms
- Forkhead Box Protein O1, Animals, Diabetes Mellitus, Type 2, Humans, Hyperglycemia, Hyperlipidemias, Hypoglycemic Agents, Insulin, Insulin Resistance, Cholesterol, HDL, Cholesterol, LDL, Liver, Male, Obesity, Oxygenases, RNA, Messenger, Triglycerides, Blotting, Western, Rats, Sprague-Dawley, Gene Expression Profiling, Hepatocytes, Atherosclerosis, Mice, Rats, Forkhead Transcription Factors, Gene Knockdown Techniques, Real-Time Polymerase Chain Reaction, In Vitro Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.